Systemic Lupus Erythematosus (SLE)

Executive summary

Lupus is one of many disorders of the immune system known as autoimmune diseases. In autoimmune diseases, the immune system turns against parts of the body it is designed to protect.
This leads to inflammation and damage to various body tissues. Lupus can affect many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain. Although people with the disease may have many different symptoms, some of the most common ones include extreme fatigue, painful or swollen joints (arthritis), unexplained fever, skin rashes, and kidney problems.



Table of content

1. Presentation ‐ Global Information 

2. Diagnosis, treatment and management 
   The Epidemiology of SLE 

3. Market 
   Global Autoimmune Market Overview

4. Products 
   Immunosuppressant Drugs

5. Products in development 
   HydroxyChloriquine (Assistance Publique Hôpitaux de Paris/Sanofi Aventis) 
   Rosuvastatin + Simvastatin (Ramathibodi Hospital/AstraZeneca) 
   Belimumab (Human Genome Sciences/GSK/CAT) 
      Clinical Data 
      About the Belimumab Phase 3 Development Program 
   Rituximab (Genentech) 
   Tacrolimus (Astellas Pharma) 
   Steroids (prednisone or prednisolone) + MMF Abatacept (Bristol‐Myers Squibb) 
   Atorvastatin - Lipitor (Buddhist Tzu Chi General Hospital / Pfizer) 
   Epratuzumab (Immunomedics / UCB) 
      Immunomedics Data 
      UCB data 
      Licensing and General info 
      Clinical Data 
   TACI‐IG (Zymogenetics / Merck Serono) 
   Prasterone GL701 (Stanford University/ Genelabs) 
      Licensing and General info 
   Etanercept (National Institute of Allergy and Infectious Diseases (NIAID)/ Florida Academic
   Dermatology Centers) 
   Rontalizumab (rhuMAb IFNalpha) ‐Omalizumab (Genentech) 
   Edratide (Teva Pharmaceuticals) 
      Clinical Data 
   IPP‐ 201101 (Immunopharma /Cephalon) 
   MEDI‐545 ‐ Sifalimumab (Corixa / Medimmune / Medarex) 
      Licensing and General info 
      Clinical Data 
   ABR‐ 215757(Active Biotech) 
      Clinical Data 
   AMG‐ 623(Amgen / Anthera Pharmaceuticals) 
   ETI‐ (Elusis Therapeutics) 
   MTRX‐1011A (Tolerx / Genentech) 
      Licensing and General info 
      Clinical Data 
   LUPUSORB (Verto Medical) 
      Clinical Data 
   CPG‐ 52364 (Coley Pharmaceutical) 
      Clinical Data 
   ANTI‐ILT7 (SBI Biotech Co / Medimmune) 
      Licensing and General info 
   CAR ANTAGONIST (Chemocentryx) 
   I‐3D (Active Biotech/ Chelsea Therapeutics) 
      Licensing and General info 
      Preclinical Data 
   IFN Alpha Kinoid (Neovacs) 
   MEDI‐546 (Medarex / MedImmune) 
      Licensing and General info 
   IRS‐954 (Dynavax) 
      Preclinial Data 
   VLST‐ 007 (VLST Corporation) 

6. Products In Discovery

List of Figures 

Figure 1: Possible events contributing to the development of systemic lupus erythematosus 
Figure 2: Global autoimmune market share by geography in 2006

List of Tables

Table 1: Diagnostic tools for lupus 
Table 2: Common Symptoms of Lupus 
Table 3: Estimated SLE prevalence in 2007
Table 4: Forecast prevalence of lupus across the seven major markets 2006-2012
Table 5: breakdown of the global autoimmune market 2002-2011
Table 6: Leading Immonosuppressant in the global autoimmune market 2005-2006
Table 7: Product in Development for Lupus Therapeutic Area



Publication date: Number of pages: Price:
2009-11-25 83 3500 euros